Tilray Inc (NASDAQ:TLRY - Get Free Report)'s stock price traded up 1.7% during trading on Tuesday . The company traded as high as $0.46 and last traded at $0.46. 7,528,632 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 29,283,931 shares. The stock had previously closed at $0.45.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on TLRY shares. Canaccord Genuity Group lifted their target price on shares of Tilray from $2.00 to $3.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Roth Capital reiterated a "neutral" rating on shares of Tilray in a report on Monday, April 14th. Finally, Piper Sandler cut their price target on Tilray from $2.00 to $1.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th.
Read Our Latest Research Report on Tilray
Tilray Price Performance
The business has a 50-day moving average of $0.62 and a 200 day moving average of $1.08. The firm has a market capitalization of $490.26 million, a P/E ratio of -1.62 and a beta of 1.88. The company has a current ratio of 2.54, a quick ratio of 1.58 and a debt-to-equity ratio of 0.10.
Tilray (NASDAQ:TLRY - Get Free Report) last issued its earnings results on Tuesday, April 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. The firm had revenue of $185.78 million during the quarter, compared to the consensus estimate of $213.38 million. On average, sell-side analysts predict that Tilray Inc will post -0.2 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tilray
Several institutional investors have recently bought and sold shares of TLRY. Lido Advisors LLC bought a new stake in shares of Tilray in the 4th quarter worth $28,000. Dudley Capital Management LLC bought a new stake in shares of Tilray in the fourth quarter valued at $29,000. Verdence Capital Advisors LLC bought a new position in shares of Tilray during the 4th quarter worth $29,000. Ameritas Advisory Services LLC bought a new stake in Tilray in the 4th quarter valued at about $32,000. Finally, Newman Dignan & Sheerar Inc. raised its stake in Tilray by 61.9% in the 4th quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company's stock valued at $35,000 after acquiring an additional 10,000 shares during the period. Institutional investors own 9.35% of the company's stock.
Tilray Company Profile
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Read More
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
